




Contents lists available at ScienceDirect

Travel Medicine and Infectious Disease

journal homepage: www.elsevier.com/locate/tmaid

World tuberculosis day 2023 – Reflections on the spread of drug-resistant tuberculosis by travellers and reducing risk in forcibly displaced populations

ARTICLE INFO

Keywords

Tuberculosis
World TB Day
Travellers
Refugees
MDR-TB
Control
Vaccines

World Tuberculosis (TB) Day, March 24th, 2023, will commemorate the day in 1882 when Professor Robert Koch announced his discovery of *Mycobacterium tuberculosis* (*Mtb*) when TB ravaged Europe. Over a century later, in 1993, the World Health Organization (WHO) declared TB a global health emergency. Since then, there have been 60 million deaths due to TB. The tragic state of affairs reflects a great paradox – that, despite affordable and effective TB treatment being available for the past seven decades, the latest 2022 WHO Annual Global Tuberculosis Report highlights that TB remains a leading cause of ill health and death from an infectious disease worldwide [1]. In 2021, the WHO estimated that 10.6 million people fell sick with TB worldwide: six million men, 3.4 million women and 1.2 million children. Multidrug-resistant TB (MDR-TB) remains a threat to global health security. Only one in three people with drug-resistant TB can access treatment; many remain undiagnosed and untreated. TB today occurs in every part of the world. An estimated 1 billion people have latent *Mtb* infection (LTBI), where the mycobacteria do not cause clinical disease but serve as a reservoir and can re-activate at any time under conditions of stress, malnutrition, poor housing, co-infections and co-morbidities, among other [35].

Millions of people with active TB continue to suffer, remain undiagnosed, and spread both forms of TB – drug-sensitive and drug-resistant. Many of these people travel across the world voluntarily for business or pleasure or are involuntarily forcibly displaced from their homes and countries due to wars, conflicts, famine, or natural disasters [2–5]. As the COVID-19 pandemic illustrates, infectious diseases do not respect international boundaries and spread rapidly between countries and continents. Regional and international travel is no doubt responsible for the spread of TB across the world [26]. However, the magnitude of the problem has been challenging to define due to the long incubation period and the insidious and slow progression of clinical disease symptoms and signs. It usually manifests many months or years after the first infection.

All travellers who move by air, land or sea face the perennial potential risk of airborne or droplet-borne transmission or acquisition of respiratory tract infections, including TB [6,7,8]. Over the past decade, multidrug-resistant TB (MDR-TB) has become an increasingly important public health problem in Asia, Africa, and Eastern Europe, exacerbated by the emergence of extensively drug-resistant TB (XDR-TB). MDR-TB is uncommon in traditional travellers; however, individual incidents involving MDR-TB and XDR-TB in airline passengers have been reported [9–11].

In 2006 the WHO published a second edition of tuberculosis and air travel: guidelines for prevention and control [12]. That provides information and specific guidance for passengers and crew, physicians, public health authorities and travel companies, although it now requires updating. Every year, millions of people travel to sporting and religious events, where mass gathering increases the risk of transmitting a range of infectious diseases, including TB. The globalisation of antibiotic-resistant bacteria at recurring mass-gathering events is known to occur. However, no specific studies have been performed on the globalisation of drug-resistant TB due to travel to and from endemic countries [13,14]. Such prospective studies are challenging to perform. Nevertheless, opportunities for developing them often occur [14].

Millions have had to travel forcibly or voluntarily for several decades across nations and continents due to conflicts, poverty, natural disasters, drought, and economic hardships. TB is a known cause of morbidity and mortality among refugees and migrant populations. The past decade has seen an increase in migration and forced displacement with potential movements of people from high TB burden settings, including MDR-TB, to TB-burdened countries. There appears to be little risk of transmission of MDR-TB to host populations from migrants to Europe, with more chance of transmission noted within migrant communities [13]. By mid-2022, United Nations High Commission for Refugees reports that 103 million people have been forcibly displaced worldwide, including

<https://doi.org/10.1016/j.tmaid.2023.102568>

Received 20 March 2023; Accepted 21 March 2023

Available online 23 March 2023

1477-8939/© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

53.2 million as internally displaced people and 32.5 million as refugees [15]. These groups are among the most vulnerable populations at increased risk of developing TB [2,4,5].

Finding and treating new TB cases among these mobile populations is one of the biggest global challenges facing public health systems. Many of them are undocumented, live in poor conditions, with limited access to health care and TB services [16,22]. In addition, they may come from weak health systems where trust in the system or access is low [17]. Ethical screening programs that objectively risk stratification for TB, improved screening or diagnostic tools, and optimal management strategies for LTBI are required to avoid stigmatising or ineffective practices. An increasing number of healthcare and humanitarian workers travel to work where the incidence of multidrug-resistant tuberculosis (MDR TB) is high, which may put them at increased risk of infection or developing clinical disease. The risk of transmission to them is ever-present due to inadequate infection control practices due to lack of respiratory protection or isolation facilities and the inability to make an early and accurate diagnosis of people with MDR TB. Increased awareness of this risk must be made to healthcare and other charity workers. They must make their travel known to their general practitioners if they develop symptoms after returning to their home countries.

The need for action has become even more pressing in the context of the 2022–2023 war in Ukraine, ongoing conflicts in other parts of the world, a global energy crisis and associated risks to food security, which are likely further to worsen some of the broader determinants of TB. There are 30 high MDR/RR-TB burden countries, which include Ukraine. Since the Russian invasion of Ukraine on February 24th, 2022, more than 10 million Ukrainian residents, including hundreds of thousands of older people, have travelled across Europe [29,31], and this is associated with the risk of exportation of all forms of TB including MDR-TB [23,24], and development of active TB in apparently healthy refugees due to stress, poor nutrition and poor housing re-activating latent TB infection [32,35].

Worryingly, for the first time since 2012, TB death rates have again started to increase globally. That is most likely due to the direct or indirect effects of the COVID-19 pandemic and the inattention of governments, donors, public health bodies and health services [1]. As occurred with other infectious and non-infectious diseases, COVID-19 had a significant impact also on TB, including emerging coinfections [18,20], with drug-resistant TB cases [18], affecting the performance of TB control programs and services in multiple countries [19], and even the notification of cases during the pandemic [20], among other consequences [28–30].

Despite advances in diagnostics and treatments, the continued global emergency of TB emphasises the need for a universally effective TB vaccine, and developing the current vaccine pipeline is a priority [21]. The United Nations General Assembly will hold the second high-level meeting on the fight against TB on September 22nd, 2023 [22,23]. The theme of the meeting is: “Advancing science, finance and innovation, and their benefits, to urgently end the global TB epidemic, in particular, by ensuring equitable access to prevention, testing, treatment and care.” World TB Day, March 24th, generates government and funder advocacy and builds public awareness about the global TB epidemic and efforts to eliminate the disease [25–27]. It is crucial that World TB Day 2023, with the theme ‘Yes! We can end TB!’ will encourage high-level leadership from committed governments and generate increased investments, faster uptake of new WHO recommendations, adoption of innovations, accelerated action, and multisectoral collaboration to combat the TB epidemic [31–34]. This year it is critical, with opportunities to raise visibility and political commitment at the 2023 UN High-Level Meeting on TB. The direct and indirect economic consequences of the COVID-19 pandemic leave policymakers in a challenging situation. The need to recover lost ground in the fight against TB across all sectors globally is clear.

Conflicts of interests

IA, FN, DYM, NK, OD, PM and AZ acknowledge support from the EU European & Developing Countries Clinical Trials Partnership-funded Pan-African Network for Rapid Research, Response, Relief and Preparedness for infectious diseases epidemics (PANDORA-ID-NET), Central African Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM-3), and East African Consortium for Clinical Research (EACCR-3) programmes. IA acknowledges support from a UK NIHR Senior Investigator Award and an NIHR Programme Grant (RID-TB). AZ receives a UK National Institutes for Health Research Senior Investigator award and is a Mahathir Foundation Science Award and Pascoal Mocumbi Prize laureate. All other authors declare no competing interests. The views expressed in this Editorial are entirely those of the authors and do not reflect the opinions of their respective institutions.

References

- [1] WHO. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
- [2] Abubakar I, Zumla A. Universal health coverage for refugees and migrants in the twenty-first century. *BMC Med* 2018 November 26 th;16(1):216. <https://doi.org/10.1186/s12916-018-1208-2>. PMID: 30474558; PMCID: PMC6260893.
- [3] Khan MS, Osei-Kofi A, Omar A, Kirkbride H, Kessel A, Abbara A, Heymann D, Zumla A, Dar O. Pathogens, prejudice, and politics: the role of the global health community in the European refugee crisis. *Lancet Infect Dis* 2016 Aug;16(8): e173–7. [https://doi.org/10.1016/S1473-3099\(16\)30134-7](https://doi.org/10.1016/S1473-3099(16)30134-7). Epub 2016 June 20th. PMID: 27339456; PMCID: PMC7106437.
- [4] Knipper M, Sedas AC, Keshavjee S, Abbara A, Almhawish N, Alshawi H, Lecca L, Wilson M, Zumla A, Abubakar I, Orcutt M. The need for protecting and enhancing TB health policies and services for forcibly displaced and migrant populations during the ongoing COVID-19 pandemic. *Int J Infect Dis* 2021 Dec;113(Suppl 1): S22–7. <https://doi.org/10.1016/j.ijid.2021.03.047>. Epub 2021 March 26th. PMID: 33775886; PMCID: PMC8752449.
- [5] Meaza A, Tola HH, Eshetu K, Mindaye T, Medhin G, Gumi B. Tuberculosis among refugees and migrant populations: systematic review. *PLoS One* 2022 Jun 9;17(6): e0268696. <https://doi.org/10.1371/journal.pone.0268696>. PMID: 35679258; PMCID: PMC9182295.
- [6] Abubakar I. Tuberculosis and air travel: a systematic review and analysis of policy. *Lancet Infect Dis* 2010 Mar;10(3):176–83. [https://doi.org/10.1016/S1473-3099\(10\)70028-1](https://doi.org/10.1016/S1473-3099(10)70028-1). PMID: 20185096.
- [7] Denholm JT, Thevarajan I. Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. *J Trav Med* May 2016;23(Issue 3). <https://doi.org/10.1093/jtm/taw008>. taw008.
- [8] Jackson C, Abubakar I. Ending tuberculosis in risk groups in Europe: challenges from travel and population movement. *Euro Surveill* 2017;22(12). <https://doi.org/10.2807/1560-7917.ES.2017.22.12.30489>.
- [9] Driver CR, Walway SE, Morgan WM, Onorato IM, Castro KG. Transmission of *Mycobacterium tuberculosis* associated with air travel. *JAMA* 1994 Oct 5;272(13): 1031–5. PMID: 8089885.
- [10] Tanne JH. Patient with tuberculosis who flew internationally has surgery and is sued by passengers. *BMJ* 2007 Jul 28;335(7612):177. <https://doi.org/10.1136/bmj.39286.532199.BD>. PMCID: PMC1934452.
- [11] Eimer J, Patimeteeporn C, Jensenius M, Gkrania-Klotsas E, Duvinand A, Barnett ED, Hochberg NS, Chen LH, Trigo-Esteban E, Gertler M, Greenaway C, Grobusch MP, Angelo KM, Hamer DH, Caumes E, Asegersson H. Multidrug-resistant tuberculosis imported into low-incidence countries—a GeoSentinel analysis, 2008–2020. *J Trav Med* 2021 Aug 27;28(6):taab069. <https://doi.org/10.1093/jtm/taab069>. PMID: 33987682; PMCID: PMC9638878.
- [12] WHO. Tuberculosis and air travel: guidelines for prevention and control. third ed. 2008 WHO REFERENCE NUMBER: WHO/HTM/TB/2008.399 <https://www.who.int/publications/i/item/9789241547505>.
- [13] Hargreaves S, Lonroth K, Nellums LB, Oлару ID, Nathavitharana RR, Norredam M, Friesland JS. Multidrug resistant tuberculosis and migration to Europe. *Clin Microbiol Infection* 2017 Mar;23(3):141–6.
- [14] Zumla A, Saeed AB, Alotaibi B, Yezli S, Dar O, Bieh K, Bates M, Tayeb T, Mwaba P, Shafi S, McCloskey B, Petersen E, Azhar EI. Tuberculosis and mass gatherings—opportunities for defining burden, transmission risk, and the optimal surveillance, prevention, and control measures at the annual Hajj pilgrimage. *Int J Infect Dis* 2016 Jun;47:86–91. <https://doi.org/10.1016/j.ijid.2016.02.003>. Epub 2016 February 9th. PMID: 26873277.
- [15] UNHCR. Refugee Statistics. 17th March, <https://www.unhcr.org/refugee-statistics/>; 2023.
- [16] Baggaley RF, Nazareth J, Divall P, Pan D, Martin CA, Volik M, Seguy NS, Yedilbayev A, Reinap M, Vovc E, Mozalevskis A, Dadu A, Waagensen E, Kruja K, Sy TR, Nellums L, Pareek M. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region. *J Trav Med* 2023 February 18 th;30(1): taac136. <https://doi.org/10.1093/jtm/taac136>. PMID: 36426801; PMCID: PMC9940698.

- [17] Scandurra G, Degeling C, Douglas P, et al. Tuberculosis in migrants – screening, surveillance and ethics. *Pneumonia* 2020;12:9. <https://doi.org/10.1186/s41479-020-00072-5>.
- [18] Ortiz-Martínez Y, Mejía-Alzate C, Vega-Vera A, Fajardo-Rivero JE, Rodríguez-Morales AJ. Drug-resistant tuberculosis and COVID-19 co-infection: a systematic review of case reports. *Int J Mycobacteriol* 2021 Apr-Jun;10(2):214–5. <https://doi.org/10.4103/ijmy.ijmy.56.21>. PMID: 34558479.
- [19] Palanca PA, Rodríguez-Morales AJ, Franco OH. The impact of the COVID-19 pandemic on tuberculosis services. *Int J Mycobacteriol* 2021 Oct-Dec;10(4):478–9. <https://doi.org/10.4103/ijmy.ijmy.223.21>. PMID: 34916472.
- [20] Ortiz-Martínez Y, Rodríguez-Morales AJ, Henao-Martínez AF. Decreased notification of TB cases during the COVID-19 pandemic. *Int J Tuberc Lung Dis* 2022 Feb 1;26(2):177–8. <https://doi.org/10.5588/ijtld.21.0651>. PMID: 35086633.
- [21] da Costa C, Onyebujoh P, Thiry G, Zumla A. Advances in development of new tuberculosis vaccines. *Curr Opin Pulm Med* 2023 March 3 rd. <https://doi.org/10.1097/MCP.0000000000000950>. Epub ahead of print. PMID: 36866744.
- [22] Abubakar I, Aldridge RW, Devakumar D, Orcutt M, Burns R, Barreto ML, Dhavan P, Fouad FM, Groce N, Guo Y, Hargreaves S, Knipper M, Miranda JJ, Madise N, Kumar B, Mosca D, McGovern T, Rubenstein L, Sammonds P, Sawyer SM, Sheikh K, Tollman S, Spiegel P, Zimmerman C. UCL–Lancet commission on migration and health. The UCL-lancet commission on migration and health: the health of a world on the move. *Lancet* 2018 Dec 15;392(10164):2606–54. [https://doi.org/10.1016/S0140-6736\(18\)32114-7](https://doi.org/10.1016/S0140-6736(18)32114-7). Epub 2018 Dec 5. PMID: 30528486; PMCID: PMC7612863.
- [23] Castro KG, Ditiu L, Sahu S, Ntoumi F, Tiberi S, O’Kane CM, Akkerman O, Manika K, Mwaba P, Davies Forsman L, Petersen E, Aklillu E, Azhar EI, Cirillo DM, Migliori GB, Abbara A, Zumla A. Optimising tuberculosis care for refugees affected by armed conflicts. *Lancet Respir Med* 2022 Jun;10(6):533–6. [https://doi.org/10.1016/S2213-2600\(22\)00104-7](https://doi.org/10.1016/S2213-2600(22)00104-7). Epub 2022 March 23rd. PMID: 35338843.
- [24] Codlin AJ, Dao TP, Vo LNQ, et al. Independent evaluation of 12 artificial intelligence solutions for the detection of tuberculosis. *Sci Rep* 2021;11:23895. <https://doi.org/10.1038/s41598-021-03265-0>.
- [25] D’Ambrosio L, Centis R, Dara M, Solovic I, Sulis G, Zumla A, Migliori GB. European policies in the management of tuberculosis among migrants. *Int J Infect Dis* 2017 Mar;56:85–9. <https://doi.org/10.1016/j.ijid.2016.11.002>. Epub 2016 November 9th. PMID: 27836793.
- [26] Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. *Emerg Infect Dis* 2002;8(8):843–9. <https://doi.org/10.3201/eid0808.020002>.
- [27] Nellums LB, Thompson H, Holmes A, Castro-Sánchez E, Otter JA, Norredam M, Friedland JS, Hargreaves S. Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis. *Lancet Infect Dis* 2018;18(7):796–811. [https://doi.org/10.1016/S1473-3099\(18\)30219-6](https://doi.org/10.1016/S1473-3099(18)30219-6) [PMC free article] [PubMed] [CrossRef] [Google Scholar].
- [28] Ortiz-Martínez Y, Mogollón-Vargas JM, López-Rodríguez M, Rodríguez-Morales AJ. A fatal case of triple coinfection: COVID-19, HIV and Tuberculosis. *Trav Med Infect Dis* 2021 Sep-Oct;43:102129. <https://doi.org/10.1016/j.tmaid.2021.102129>. Epub 2021 Jun 24. PMID: 34174407; PMCID: PMC8223034.
- [29] Pandey A, Wells CR, Stadnytskyi V, Moghadas SM, Marathe MV, Sah P, Crystal W, Meyers LA, Singer BH, Nesterova O, Galvani AP. Disease burden among Ukrainians forcibly displaced by the 2022 Russian invasion. *Proc Natl Acad Sci U S A* 2023 February 21 st;120(8):e2215424120. <https://doi.org/10.1073/pnas.2215424120>. Epub 2023 February 13th. PMID: 36780515; PMCID: PMC9974407.
- [30] Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialised countries. *Emerg Infect Dis* 2012;18:1422–9.
- [31] Piotrowicz K, Semeniv S, Kupis R, Ryś M, Perera I, Gryglewska B, Gaşowski J. Disease burden in older Ukrainian refugees of war: a synthetic reanalysis of public records data. *Lancet Healthy Longev* 2022 Oct;3(10):e667–73. [https://doi.org/10.1016/S2666-7568\(22\)00187-8](https://doi.org/10.1016/S2666-7568(22)00187-8). Epub 2022 September 16th. PMID: 36122579.
- [32] Rao M, Ippolito G, Mfinanga S, Ntoumi F, Yeboah-Manu D, Vilaplana C, Zumla A, Maeurer M. Latent TB Infection (LTBI) - Mycobacterium tuberculosis pathogenesis and the dynamics of the granuloma battleground. *Int J Infect Dis* 2019 Mar;80S:S58–61. <https://doi.org/10.1016/j.ijid.2019.02.035>. Epub 2019 February 26th. PMID: 30822547.
- [33] Shaban RZ, Sotomayor-Castillo CF, Malik J, Li C. Global commercial passenger airlines and travel health information regarding infection control and the prevention of infectious disease: what’s in a website? *Trav Med Infect Dis* 2020 Jan-Feb;33:101528. <https://doi.org/10.1016/j.tmaid.2019.101528>. Epub 2019 November 21st. PMID: 31760126; PMCID: PMC7110852.
- [34] Zumla A, Abubakar I. Improving access to multi-drug resistant tuberculosis diagnostic and health services for refugees and migrants. *BMC Med* 2018 November 30 th;16(1):221. <https://doi.org/10.1186/s12916-018-1218-0>. PMID: 30497477; PMCID: PMC6267830.
- [35] Grange J, Zumla A. Tuberculosis and the poverty-disease cycle. *J R Soc Med* 1999 Mar;92(3):105–7. doi: 10.1177/014107689909200301. PMID: 10396250; PMCID: PMC1297096.

Alfonso J. Rodríguez-Morales ^{*1}

Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de Las Américas-Institución Universitaria Vision de Las Américas, Pereira, Risaralda, Colombia
Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru
Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, P.O. Box 36, Lebanon

Aula Abbara

Syria Public Health Network and Imperial College, London, UK
Division of Infection and Immunity, Imperial College London, London, United Kingdom

Francine Ntoumi

Fondation Congolaise pour la Recherche Médicale, Brazzaville, People’s Republic of Congo
Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany

Nathan Kapata

National Public Health Institute, Ministry of Health, Lusaka, Zambia
UNZA-UCLMS Research and Training Program, UTH, Lusaka, Zambia

Peter Mwaba

UNZA-UCLMS Research and Training Program, UTH, Lusaka, Zambia
Lusaka Apex Medical University, Faculty of Medicine, Lusaka, Zambia

Dorothy Yeboah-Manu

Bacteriology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana

Markus Maeurer

Champalimaud Centre for the Unknown, Lisbon, Portugal
Medizinische Klinik, Johannes Gutenberg University Mainz, Germany

Osman Dar

Global Operations, United Kingdom Health Security Agency, London, UK
Global Health Programme, Royal Institute of International Affairs, London, United Kingdom

Ibrahim Abubakar

Faculty of Population Health Sciences, University College London (UCL), London, United Kingdom

Alimuddin Zumla

Department of Infection, Division of Infection and Immunity, University College London, UK

^a NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom

^{*} Corresponding author. Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Peru.
E-mail address: arodriguezmo@cientifica.edu.pe (A.J. Rodríguez-Morales).

¹ Editor-in-Chief, Travel Medicine and Infectious Diseases.